ProductsClinical ResultsPractitionersVideosHow to BuyCompany News

Press Releases

Artegraft® Revamps and Re-Launches Website

Natural Collagen Vascular Graft Leader Enhances to Make it a Source of Information for Surgeons and Vascular Specialists.

Artegraft®, Inc. — manufacturer of the first vascular graft approved by the FDA — proudly announces the redesign and re-launch of its website – Easy to navigate, the website offers product information, clinical results, FAQs and other resources so that surgeons, nephrologists, nurses, dialysis technicians and other medical professionals can understand the differences between an Artegraft and other vascular grafts.

Additionally, visitors to will find expert testimonials, purchasing information, company news, manufacturing process details and more. Visitors can also sign up for the new quarterly e-newsletter, BCA RoundUp: Vascular News from Artegraft, on the site.

“We want our website to not only provide information on our products, but to offer surgeons and vascular specialists supportive tools to help them treat patients who require vascular grafts,” said Artegraft President and Chief Executive Officer Richard A. Gibson. “We’re very excited to debut a website where visitors can find valuable information on treating patients who are in need of their informed care.”

Done in partnership with the company’s recently appointed marketing agency of record, SGWMcGuggan Integrated Marketing Communications, the new website launches on the heels of several new developments within Artegraft, Inc. In addition to the website, Artegraft has also launched a YouTube channel, which features surgical videos, demos and brief interviews with those who have experienced Artegraft.

A recently published clinical study also validates the long-term patency advantages of Artegraft’s natural collagen graft, commonly referred to as the BCA Graft or Fistula in a Bottle™. The three-year prospective, randomized clinical study was published in the June 2011 issue of the Journal of Vascular Surgery. The study concluded that the BCA graft had significantly higher primary and assisted patency rates than the ePTFE graft, resulting in fewer interventions, better patient outcomes and, ultimately, long-term cost benefits for hospitals, ambulatory surgery and dialysis centers.

To view the new website, simply go to To watch videos on the Artegraft YouTube channel, please visit

Artegraft - Press Releases


Archived News


  Frequently Asked Questions Our Manufacturing Process